Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer

Cancer Immunology, Immunotherapy

Volumn 64, Issue 12, 2015, Pages 1495-1504

  Knutson, Keith L ^a,b   Maurer, Matthew J ^c   Preston, Claudia C ^b   Moysich, Kirsten B ^d   Goergen, Krista ^c   Hawthorne, Kieran M ^c   Cunningham, Julie M ^c   Odunsi, Kunle ^d   Hartmann, Lynn C ^c   Kalli, Kimberly R ^c   Oberg, Ann L ^c   Goode, Ellen L ^c  

^a Vaccine and Gene Therapy Institute of Florida   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

CD8; Immune suppression; Treg; Tumor microenvironment

Indexed keywords

INTERLEUKIN 10;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE NUCLEOTIDE POLYMORPHISM; CD4 CD8 RATIO; CONFOCAL MICROSCOPY; CYTOLOGY; GENETIC VARIATION; GENETICS; GENOTYPE; IMMUNOLOGY; LYMPHOCYTE COUNT; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOPHYSIOLOGY; PROGNOSIS;

CD4-CD8 RATIO; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; INTERLEUKIN-10; LYMPHOCYTE COUNT; MICROSCOPY, CONFOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; T-LYMPHOCYTES, REGULATORY;

EID: 84947041471     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1753-x     Document Type: Article

References (52)

1. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC (2007) Current management strategies for ovarian cancer. Mayo Clin Proc 82:751–770
2. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519–2529. doi:10.1056/NEJMra041842
3. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 21:3194–3200. doi:10.1200/JCO.2003.02.153
4. Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P et al (2010) Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst 102:1547–1556. doi:10.1093/jnci/djq362
5. Trimble EL, Birrer MJ, Hoskins WJ, Marth C, Petryshyn R, Quinn M et al (2010) Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. Int J Gynecol Cancer 20:1290–1298. doi:10.1111/IGC.0b013e3181ee1c01
6. Winter WE III, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:3621–3627. doi:10.1200/JCO.2006.10.2517
7. Nelson BH (2015) New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer. Curr Opin Immunol 33C:93–100. doi:10.1016/j.coi.2015.02.004
8. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203–213. doi:10.1056/NEJMoa020177
9. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538–18543. doi:10.1073/pnas.0509182102
10. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL (2011) Immunity and immune suppression in human ovarian cancer. Immunotherapy 3:539–556. doi:10.2217/imt.11.20
11. Charbonneau B, Goode EL, Kalli KR, Knutson KL, Derycke MS (2013) The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol 33:137–164
12. Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, Behrens MD, Knutson KL (2014) Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res 74:2974–2985. doi:10.1158/0008-5472.CAN-13-2564
13. + T lymphocytes. Clin Exp Immunol 150:523–530. doi:10.1111/j.1365-2249.2007.03521.x
14. Chen F, Hou M, Ye F, Lv W, Xie X (2009) Ovarian cancer cells induce peripheral mature dendritic cells to differentiate into macrophagelike cells in vitro. Int J Gynecol Cancer 19:1487–1493. doi:10.1111/IGC.0b013e3181bb70c6
15. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949. doi:10.1038/nm1093
16. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A et al (2006) Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 176:5023–5032. doi:10.4049/jimmunol.176.8.5023
17. Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ et al (2008) Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 68:7684–7691. doi:10.1158/0008-5472.CAN-08-1167
18. Ko SY, Ladanyi A, Lengyel E, Naora H (2014) Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am J Pathol 184:271–281. doi:10.1016/j.ajpath.2013.09.017
19. Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H et al (2011) Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 186:6905–6913. doi:10.4049/jimmunol.1100274
20. Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T, Lu J, Liu J (2013) Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat 12:259–267. doi:10.7785/tcrt.2012.500312
21. Le Page C, Marineau A, Bonza PK, Rahimi K, Cyr L, Labouba I et al (2012) BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PLoS ONE 7:e38541. doi:10.1371/journal.pone.0038541
22. − T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 67:1–12. doi:10.1016/j.humimm.2005.11.005
23. Murray PJ, Wynn TA (2011) Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11:723–737. doi:10.1038/nri3073
24. − T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS ONE 8:e80063. doi:10.1371/journal.pone.0080063
25. + regulatory T cells in human ovarian carcinoma. Cancer Res 65:5020–5026. doi:10.1158/0008-5472.CAN-04-4043
26. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E et al (2005) The expression of the regulatory T cell-specific forkhead box transcription factor FOXp3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11:8326–8331. doi:10.1158/1078-0432.CCR-05-1244
27. Yang R, Cai Z, Zhang Y, Yutzy WHt, Roby KF, Roden RB (2006) CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1 + CD11b + myeloid cells. Cancer Res 66:6807–6815. doi:10.1158/0008-5472.CAN-05-3755
28. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307. doi:10.1038/nri1806
29. Zou W, Machelon V, Coulomb-L’Hermin A, Borvak J, Nome F, Isaeva T et al (2001) Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7:1339–1346. doi:10.1038/nm1201-1339
30. Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL (2015) Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol 194:2985–2991. doi:10.4049/jimmunol.1403134
31. Knutson KL, Disis ML, Salazar LG (2007) CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother 56:271–285. doi:10.1007/s00262-006-0194-y
32. Savage PA, Malchow S, Leventhal DS (2013) Basic principles of tumor-associated regulatory T cell biology. Trends Immunol 34:33–40. doi:10.1016/j.it.2012.08.005
33. Le DT, Jaffee EM (2012) Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 72:3439–3444. doi:10.1158/0008-5472.CAN-11-3912
34. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D et al (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115:3623–3633. doi:10.1172/JCI25947
35. Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, Disis ML (2006) IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 177:84–91
36. Goode EL, DeRycke M, Kalli KR, Oberg AL, Cunningham JM, Maurer MJ et al (2013) Inherited variants in regulatory T cell genes and outcome of ovarian cancer. PLoS ONE 8:e53903. doi:10.1371/journal.pone.0053903
37. Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC et al (2014) Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunol Res 2:332–340. doi:10.1158/2326-6066.CIR-13-0136
38. Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, Fridley BL et al (2010) Inherited determinants of ovarian cancer survival. Clin Cancer Res 16:995–1007. doi:10.1158/1078-0432.CCR-09-2553
39. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, Podratz KC, Cliby WA (2006) Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107:77–85. doi:10.1097/01.AOG.0000192407.04428.bb
40. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY (1999) Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72:278–287. doi:10.1006/gyno.1998.5145
41. Chang SJ, Bristow RE (2012) Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining ‘optimal’ residual disease. Gynecol Oncol 125:483–492. doi:10.1016/j.ygyno.2012.02.024
42. Jelovac D, Armstrong DK (2011) Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 61:183–203. doi:10.3322/caac.20113
43. Nakayamada S, Takahashi H, Kanno Y, O’Shea JJ (2012) Helper T cell diversity and plasticity. Curr Opin Immunol 24:297–302. doi:10.1016/j.coi.2012.01.014
44. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S et al (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114:1141–1149. doi:10.1182/blood-2009-03-208249
45. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E et al (2009) A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 41:996–1000. doi:10.1038/ng.424
46. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C et al (2010) Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 42:880–884. doi:10.1038/ng.666
47. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K et al (2010) A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 42:874–879. doi:10.1038/ng.668
48. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K et al (2013) GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 45:362–370, 70e1–2. doi:10.1038/ng.2564
49. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z et al (2013) Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun 4:1627. doi:10.1038/ncomms2613
50. Yang AS, Lattime EC (2003) Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 63:2150–2157
51. + T cells. J Immunol 160:3188–3193
52. + regulatory T cells. J Immunol 177:896–904